<DOC>
	<DOCNO>NCT00728936</DOCNO>
	<brief_summary>First-in-humans , phase 1 , dose-escalation study 4 dose level single-agent IMO-2125 .</brief_summary>
	<brief_title>Placebo-controlled , Dose-escalation Study Safety IMO-2125 Hepatitis C-infected Patients</brief_title>
	<detailed_description>First-in-humans , phase 1 , dose-escalation study 4 dose level single-agent IMO-2125 . Patients proceed screen period , treatment period , follow-up period approximately 4 month ' duration . There 4 dose cohort include active drug placebo dosing .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>HCVpositive Nonresponder standarddose pegylated interferonα2a α2b combination standarddose ribavirin Human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( HbsAg ) Inadequate bone marrow , liver , renal function Treatment IFNbased experimental antiviral therapy within 30 day Other significant medical disease Known alcohol drug abuse within past 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>unresponsive pegylated interferon ribavirin therapy</keyword>
	<keyword>HCV</keyword>
</DOC>